Biolegend, 505803, Biotin anti-mouse IFN-γ Antibody
50microg
Catalog Number: 505803
Loading…
| Verified Reactivity | Mouse |
|---|---|
| Antibody Type | Monoclonal |
| Host Species | Rat |
| Immunogen | E. coli-expressed, recombinant mouse IFN-γ |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. |
| Preparation | The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. |
| Concentration | 0.5 mg/ml |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze. |
| Application | ELISA Detection, ELISPOT Detection, ICFC |
| Recommended Usage | Each lot of this antibody is quality control tested by ELISA assay. For use as an ELISA detection antibody, a concentration range of 0.5-2.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IFN-γ recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate.For use as an ELISPOT detection antibody, a concentration range of 1-4 µg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application. |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application Notes |
|---|
| ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended. |
| Application References(PubMed link indicates BioLegend citation) | Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC) |
|---|
| Product Citations | Lew MH, et al. 2018. Pathog Glob Health. :1. PubMed Cautivo KM, et al. 2022. Immunity. 55:254. PubMed Altemus J, et al. 2022. J Cell Physiol. 237:3001. PubMed Campisi L, et al. 2022. Nature. 606:945. PubMed Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed Dong L, et al. 2021. Cancer Cell. . PubMed Peng X, et al. 2010. J Pharmacol Exp Ther. 13.86527778. PubMed Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed Dong S, et al. 2020. J Control Release. 328:653. PubMed Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed Berdasco C, et al. 2020. Front Cell Infect Microbiol. 0.681944444. PubMed Montfort M, et al. 2004. J Immunol. 173:4084. PubMed Tanner S, et al. 2016. J Histochem Cytochem. 64(12):753-767. PubMed Thornton T, et al. 2016. Nat Commun. 7:10553. PubMed Plantinga T, et al. 2011. Clin Vaccine Immunol. 1.18125. PubMed Wang P, et al. 2018. Theranostics. 0.488194444. PubMed Cooley L, et al. 2016. Sci Rep. 6: 25840. PubMed Guo H, et al. 2014. J Virol. 88:12006. PubMed |
|---|
| RRID | AB_315397 (BioLegend Cat. No. 505803) AB_315398 (BioLegend Cat. No. 505804) |
|---|
| Structure | Cytokine; dimer; 40-80 kD (Mammalian) |
|---|
| Bioactivity | Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs |
|---|
| Cell Sources | CD8+ and CD4+ T cells, NK cells |
|---|
| Cell Targets | T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts |
|---|
| Receptors | IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1) |
|---|
| Cell Type | Tregs |
|---|
| Biology Area | Cell Biology, Immunology, Neuroinflammation, Neuroscience |
|---|
| Molecular Family | Cytokines/Chemokines |
|---|
| Antigen References | 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151. |
|---|
| Regulation | Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone |
|---|
| Gene ID | 15978 |
|---|
| UniProt | View information about IFN-gamma on UniProt.org |
|---|
| Clone | XMG1.2 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF) |
|---|
| Isotype | Rat IgG1, κ |
|---|
